CPC is founded by Dr. Shawn Lee who has dedicated the past 18 years to peptide science. During this time, he set up stringent quality standards for commercial peptide production and directed the manufacturing of both research and cGMP grade peptides. CPC currently has a state of the art, 143,600 sq ft production campus with >150 full time employees. CPC has produced thousands of peptides ranging in quantity from milligrams to multiple kilograms with purities up to >99%. CPC possesses the ability to perform almost every available peptide modification with the exception of radio labeling. CPC is currently the preferred vendor for many of the world's top Pharmaceutical and Biotech companies and many Universities.
In July 2012, CPC started the development of a new 163,300 sq ft facility to house phase 3 clinical projects. Through this expansion, CPC is able to establish itself as a world leader in the peptide therapeutic market and will be able to provide our customers with a complete solution to their peptide needs from research quantities to commercial scale. A versatile approach adopted by CPC in peptide manufacture employing different synthesis technologies coupled with extensive experience in peptide modifications and high quality bulk raw material sourcing allow us to extend competitive pricing to any stage of development for a peptide project.